Pinnacle Medicines, a Pioneer of Oral Peptide Therapeutics, Announces Oversubscribed $89 Million Series B Financing to Advance Pipeline into Clinical Trials

Financing co-led by LAV and Foresite Capital with participation from Quan Capital, Hankang Capital, RA Capital Management, Logos Capital and existing investors including OrbiMed Company has raised $134 million to date following incubation by OrbiMed and other healthcare specialist...

Read More